Assessment of human effective absorbed dose of 67?Ga–ECC based on biodistribution rat data

详细信息    查看全文

• 作者：Saeed Shanehsazzadeh ; Hassan Yousefnia ; Afsaneh Lahooti…
• 关键词：Biodistribution ; Effective absorbed dose ; Gallium 67 ; ethylenecysteamine cysteine
• 刊名：Annals of Nuclear Medicine
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：29
• 期：2
• 页码：118-124
• 全文大小：418 KB
• 参考文献：1. Stabin MG, Tagesson M, Thomas SR, Ljungberg M, Strand SE. Radiation dosimetry in nuclear medicine. Appl Radiat Isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 1999;50:73-7. CrossRef
  2. Eberlein U, Broer JH, Vandevoorde C, Santos P, Bardies M, Bacher K, et al. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine—a review. Eur J Nucl Med Mol. 2011;I(38):2269-1. CrossRef
  3. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med: official publication, Society of Nuclear Medicine. 1996;37:538-6.
  4. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine; 1988.
  5. Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. In Sixth International Radiopharmaceutical Dosimetry Symposium Oak Ridge, Oak Ridge Associated Universities, 1996; 705-6.
  6. Lahooti A, Shanehsazzadeh S, Oghabian MA, Allen BJ. Assessment of human effective absorbed dose of Tc-99?m-USPIO based on biodistribution rat data. J Labelled Compd Rad. USA: Wiley; 2013. p. S258.
  7. Stabin MG. The importance of patient-specific dose calculations in nuclear medicine. Nucl Eng Technol. 2008;40:527. CrossRef
  8. Lederer CM, Shirley VS, Browne E, Shihab-Eldin AA. Table of isotopes. New York: Wiley; 1978. p. 67.
  9. Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on Auger electron emission. J Nucl Med. 2000;41:1519-1.
  10. Mez-Tejedor GGG, Fuss MC. Radiation Damage in Biomolecular Systems. USA: Springer; 2012. CrossRef
  11. Firestone RB, Shirley VS, Baglin CM, Chu SF, Zipkin J. Table of Isotopes, vol. II. New York: Willey; 1996.
  12. Cutler CS, Giron MC, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, et al. Evaluation of gallium-68 tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake. Nucl Med Biol. 1999;26:305-6. CrossRef
  13. Tsang BW, Mathias CJ, Green MA. A gallium-68 radiopharmaceutical that is retained in myocardium: 68?Ga [(4, 6-MeO2sal) 2BAPEN]. J Nucl Med: official publication, Society of Nuclear Medicine. 1993;34:1127.
  14. Jalilian A, Shanehsazzadeh S, Akhlaghi M, Garoosi J, Rajabifar S, Tavakoli M. Preparation and evaluation of [67?Ga]-DTPA-β-1-24-corticotrophin in normal rats. Radiochim Acta. 2008;96:435-.
  15. Shanehsazzadeh S, Jalilian AR, Sadeghi HR, Allahverdi M. Determination of human absorbed dose of 67GA-DTPA-ACTH based on distribution data in rats. Radiat Prot Dosim. 2009;134:79-6. CrossRef
  16. Jalilian A, Shanehsazzadeh S, Akhlaghi M, Garousi J, Rajabifar S, Tavakoli M. Preparation and biodistribution of [67?Ga]-DTPA-gonadorelin in normal rats. J Radioanal Nucl Ch. 2008;278:123-. CrossRef
  17. Shanehsazzadeh S, Jalilian A. Development of [67ga]-Dtpa-Gonadorelin in Normal Rats. J Labelled Compd Rad. 2009;52(Suppl 1):S326.
  18. Shanehsazzadeh S, Lahooti A, Sadeghi HR, Jalilian AR. Estimation of human effective absorbed dose of 67?Ga–cDTPA–gonadorelin based on biodistribution rat data. Nucl Med Commun. 2011;32:37-3. CrossRef
  19. Shanehsazzadeh S, Oghabian MA, Lahooti A, Abdollahi M, Haeri SA, Amanlou M, et al. Estimated background doses of [67?Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers. Nucl Med Commun. 2013;34:915-5.
  20. Jalilian A, Yousefnia H, Zolghadri S, Khoshdel M, Bolourinovin F, Rahiminejad A. Development of radiogallium–ethylenecysteamine cysteine complex as a possible renal imaging agent. J Radioanal Nucl Ch. 2010;284:49-4. CrossRef
  21. Shanehsazzadeh S, Oghabian MA, Lahooti A, Allen BJ. Development of ultra small super paramagnetic iro
• 刊物主题：Nuclear Medicine; Imaging / Radiology;
• 出版者：Springer Japan
• ISSN：1864-6433

文摘

Objective In a diagnostic context, determination of absorbed dose is required before the introduction of a new radiopharmaceutical to the market to obtain marketing authorization from the relevant agencies. In this work, the absorbed dose of [67?Ga]-ethylenecysteamine cysteine [(67?Ga)ECC] to human organs was determined by using distribution data for rats. Methods For biodistribution data, the animals were sacrificed by CO2 asphyxiation at selected times after injection (0.5, 2 and 48?h, n?=?3 for each time interval), then the tissue (blood, heart, lung, brain, intestine, feces, skin, stomach, kidneys, liver, muscle and bone) were removed. The absorbed dose was determined by Medical Internal Radiation Dose (MIRD) method after calculating cumulated activities in each organ. Results Our prediction shows that a 185-MBq injection of 67Ga-ECC into the humans might result in an estimated absorbed dose of 0.029?mGy in the whole body. The highest absorbed doses are observed in the spleen and liver with 33.766 and 16.847?mGy, respectively. Conclusion The results show that this radiopharmaceutical can be a good SPECT tracer since it can be produced easily and also the absorbed dose in each organ is less than permitted absorbed dose.